Citadel Advisors’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-112,000
| Closed | -$11.4M | – | 15469 |
|
|
2023
Q2 | $11.4M | Sell |
112,000
-27,600
| -20% | -$2.61M | ﹤0.01% | 2504 |
|
|
2023
Q1 | $12.7M | Sell |
139,600
-57,400
| -29% | -$3.37M | ﹤0.01% | 2479 |
|
|
2022
Q4 | $7.48M | Buy |
197,000
+27,900
| +16% | +$960K | ﹤0.01% | 3230 |
|
|
2022
Q3 | $4.25M | Buy |
169,100
+105,800
| +167% | +$2.93M | ﹤0.01% | 4150 |
|
|
2022
Q2 | $1.92M | Sell |
63,300
-79,200
| -56% | -$2.36M | ﹤0.01% | 5622 |
|
|
2022
Q1 | $4.67M | Sell |
142,500
-58,400
| -29% | -$1.73M | ﹤0.01% | 4305 |
|
|
2021
Q4 | $5.3M | Buy |
200,900
+124,100
| +162% | +$9.6M | ﹤0.01% | 4188 |
|
|
2021
Q3 | $7.73M | Buy |
76,800
+19,900
| +35% | +$2.33M | ﹤0.01% | 3509 |
|
|
2021
Q2 | $8.05M | Buy |
56,900
+30,600
| +116% | +$3.46M | ﹤0.01% | 3466 |
|
|
2021
Q1 | $2.62M | Sell |
26,300
-4,800
| -15% | -$560K | ﹤0.01% | 5762 |
|
|
2020
Q4 | $3.85M | Sell |
31,100
-18,800
| -38% | -$2.47M | ﹤0.01% | 4143 |
|
|
2020
Q3 | $4.86M | Buy |
49,900
+13,000
| +35% | +$1.62M | ﹤0.01% | 3204 |
|
|
2020
Q2 | $5.76M | Sell |
36,900
-115,500
| -76% | -$17.6M | ﹤0.01% | 2894 |
|
|
2020
Q1 | $22M | Buy |
152,400
+13,600
| +10% | +$2.63M | 0.01% | 1165 |
|
|
2019
Q4 | $28.4M | Buy |
138,800
+99,400
| +252% | +$18.1M | 0.01% | 1171 |
|
|
2019
Q3 | $3.16M | Buy |
39,400
+3,400
| +9% | +$289K | ﹤0.01% | 3762 |
|
|
2019
Q2 | $3.4M | Buy |
36,000
+12,500
| +53% | +$1.08M | ﹤0.01% | 3664 |
|
|
2019
Q1 | $2.01M | Buy |
23,500
+16,900
| +256% | +$1.4M | ﹤0.01% | 4453 |
|
|
2018
Q4 | $370K | Sell |
6,600
-7,300
| -53% | -$446K | ﹤0.01% | 6900 |
|
|
2018
Q3 | $1.14M | Buy |
+13,900
| New | +$980K | ﹤0.01% | 5313 |
|
Other funds holding RETA
Citadel Advisors's RETA Position: Q3 2023 in Review
Citadel Advisors sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2023, closing a stake of 571,529 shares — an estimated $58.3M sold.
Citadel Advisors first reported a position in RETA in Q3 2017 and held it in 22 quarters. The position peaked at $58.3M in Q2 2023. 2 funds tracked by Wall St. Rank hold RETA as of Q3 2023.
- Citadel Advisors reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2023 after selling out during the quarter.
- Citadel Advisors sold 571,529 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2023, an estimated $58.3M.
- Citadel Advisors first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q3 2017 and held it in 22 quarters.
- Citadel Advisors's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $58.3M in Q2 2023.
- 2 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2023.
Based on Citadel Advisors's 13F filing for Q3 2023, filed 14 Nov 2023.